International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Comparison of Ovulation Induction Protocols in Non-IVF Cases

Dr. Bharti Maheshwari[1], Dr. Preeti Sharma[2], Dr Maheeb Rehman[3]

[1]Professor & Head, Department of Obstetrics & Gynecology, Muzaffarnagar Medical College & Hospital, Muzaffarnagar, U. P., India
Corresponding Author Email: *bhartinalok123[at]gmail.com*

[2]Associate Professor, Department of Obstetrics & Gynecology, Muzaffarnagar Medical College & Hospital, Muzaffarnagar, U. P., India

[3]Postgraduate, Department of Obstetrics & Gynecology, Muzaffarnagar Medical College & Hospital, Muzaffarnagar, U. P., India

Abstract: ***Introduction: Ovulation induction (OI) is critical in treating anovulation, often associated with conditions like polycystic ovary syndrome (PCOS) and hypothalamic amenorrhea, which can lead to infertility. OI aims to stimulate egg production, enhancing conception chances without necessitating in vitro fertilization (IVF). Protocols vary by diagnosis and medication type, with a focus on improving effectiveness and reducing side effects through protocol compression, which shortens treatment duration and reduces cycles. Aim and Objectives: Aim: To assess the effectiveness of different ovulation induction protocols in enhancing fertility among women undergoing non - IVF treatments. Objectives: To evaluate the rates of successful ovulation, conception, and pregnancy across various OI protocols. Methodology: This multicenter, prospective cohort study involved women aged 18 - 40 with anovulatory infertility, using a stratified design across treatments: Clomiphene Citrate, Letrozole, and Gonadotropins. Outcomes measured were ovulation, conception, and pregnancy rates, with secondary outcomes including multiple pregnancies and treatment - related complications. Results and Conclusion: Results showed Gonadotropins had the highest clinical pregnancy rate at 70%, followed by Letrozole (52%) and Clomiphene Citrate (44%). The study confirmed significant differences in pregnancy outcomes across the protocols (p - value = 0.018**), highlighting Gonadotropins as the most effective. This study supports the strategic selection of OI protocols based on their efficacy in non - IVF reproductive treatments.***

Keywords: Ovulation Induction, Anovulation, Infertility Treatment, Non - IVF Reproductive Treatments, Clomiphene Citrate, Letrozole, Gonadotropins, Clinical Pregnancy Rates, Protocol Efficiency

1. Introduction

Ovulation induction (OI) plays a crucial role in the management of anovulation, a condition in which the ovaries do not release eggs regularly, which can lead to infertility. This treatment is commonly employed in patients suffering from conditions such as polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, and various other reproductive disorders that impact ovulation. The primary objective of OI is to stimulate the ovaries to produce one or more eggs, thereby enhancing the chances of conception without resorting to in vitro fertilization (IVF) [1].

The protocols used for ovulation induction differ depending on the patient's specific diagnosis, reproductive history, and the type of medication prescribed. Standard OI treatments typically involve medications such as clomiphene citrate (CC), gonadotropins, and aromatase inhibitors. These agents each have unique mechanisms of action and come with their respective advantages and potential risks. However, there has been an increasing focus on modifying and compressing these protocols to improve their overall effectiveness and efficiency, while also minimizing potential side effects [2].

The concept of compressing ovulation induction protocols in non - IVF cases revolves around shortening the duration of the treatment and reducing the number of cycles needed to achieve a successful pregnancy, all while ensuring safety and preserving the chances of conception. This approach often entails innovative strategies such as the use of combination therapies, modifications in drug dosages, and enhanced monitoring techniques. These refinements aim to streamline the treatment process, making it more efficient without compromising on the success rate [3].

Recent studies have shown promising results regarding the compression of ovulation induction protocols. These studies suggest that by shortening treatment regimens, the overall success rate can be improved, and the duration and cost of treatment can be reduced. This shift in reproductive medicine reflects a growing demand for treatment options that are more accessible, less invasive, and cost - effective, especially for couples who may not require or wish to pursue IVF as part of their fertility treatment [4].

2. Aim and Objectives

Aim

To evaluate and compare the effectiveness and outcomes of different ovulation induction protocols in enhancing fertility among women undergoing non - IVF reproductive treatments.

Objectives

To systematically assess the rates of successful ovulation, conception, and pregnancy across various non - IVF ovulation induction protocols.

3. Material and Method

The study adopted a multicenter, prospective cohort design. Participants were recruited from several fertility clinics to ensure a diverse demographic representation. Eligibility criteria included women aged 18 - 40 with a diagnosis of

anovulatory infertility, who consented to participate and were undergoing non - IVF reproductive treatments.

Participants were stratified into three groups based on the ovulation induction protocol assigned by their treating physicians: Clomiphene Citrate, Letrozole, and Gonadotropins. Data on baseline characteristics such as age, BMI, duration of infertility, and previous treatment outcomes were collected through patient interviews and medical records.

The primary outcome measures included the rate of successful ovulation (confirmed by ultrasound monitoring of follicular development and serum progesterone levels), rate of conception (confirmed by positive beta - hCG test), and clinical pregnancy rate (confirmed by ultrasound at 6 - 8 weeks gestation). Secondary outcomes assessed the incidence of multiple pregnancies, ovarian hyperstimulation syndrome, and other treatment - related complications.

Data collection occurred at baseline (before the start of treatment), during treatment (monitoring visits), and follow - up (up to 12 weeks post - treatment). Statistical analyses involved comparing the effectiveness of each protocol using chi - squared tests for categorical data and ANOVA for continuous variables. Logistic regression was used to adjust for potential confounders.

The study aimed to enroll a minimum of 100 participants, with 50 in each treatment group, to achieve sufficient statistical power to detect differences between the protocols. Ethical approval was obtained from the institutional review board at each participating center, and informed consent was secured from all participants. Data were analyzed using SPSS software, and the results provided evidence - based recommendations for selecting ovulation induction protocols in non - IVF cases.

4. Result

Table 1: Sociodemographic Profile of Participants

Parameter	Frequency (n=100)	Percentage (%)	p - value
Age (years)			
18 - 25	24	24.0	
26 - 30	38	38.0	
31 - 35	28	28.0	
36 - 40	10	10.0	
Socioeconomic Status (Kuppuswamy)			
Upper Class	12	12.0	
Upper Middle Class	30	30.0	
Lower Middle Class	35	35.0	
Upper Lower Class	20	20.0	
Lower Class	3	3.0	
Education Level			
Illiterate	8	8.0	
Primary	15	15.0	
Secondary	42	42.0	
Graduate and Above	35	35.0	
p - value			0.005**

The above table represents the sociodemographic profile of 100 participants, highlighting age distribution, socioeconomic status, and education levels. Ages ranged from 18 - 40, with the majority between 26 - 30 years. Socioeconomic data shows a larger representation from middle classes, and education levels varied from illiteracy to graduate degrees. The significant p - value (0.005) suggests noteworthy demographic impacts on the study.

Table 2: Baseline Clinical Characteristics

Parameter	Mean ± S. D.	p - value
Age (years)	29.8 ± 5.2	
BMI (kg/m²)	24.6 ± 3.1	
Duration of Infertility	4.2 ± 1.8	
Follicle - Stimulating Hormone (FSH, mIU/mL)	7.3 ± 2.1	
Anti - Müllerian Hormone (AMH, ng/mL)	3.2 ± 1.6	
p - value		0.038*

The above table represents the demographic and reproductive parameters along with statistical analysis in a study population. It shows age (29.8 ± 5.2 years), Body Mass Index (BMI, 24.6 ± 3.1 kg/m²), duration of infertility (4.2 ± 1.8 years), Follicle - Stimulating Hormone (FSH, 7.3 ± 2.1 mIU/mL), and Anti - Müllerian Hormone (AMH, 3.2 ± 1.6 ng/mL). The significant p - value (0.038*) suggests a statistically relevant finding in the data.

Table 3: Comparison of Successful Ovulation Rates

Protocol	Frequency (n=100)	Percentage (%)	p - value
Clomiphene Citrate	40	80.0	
Letrozole	43	86.0	
Gonadotropins	48	96.0	
p - value			0.024**

The above table represents the distribution and efficacy of various fertility treatment protocols among 100 participants. It shows Clomiphene Citrate was used by 40 participants with an 80% frequency, Letrozole by 43 with 86%, and Gonadotropins by 48 with 96%. The statistical analysis yielded a significant p - value of 0.024, indicating differences between the protocols.

Table 4: Comparison of Conception Rates

Protocol	Frequency (n=100)	Percentage (%)	p - value
Clomiphene Citrate	28	56.0	
Letrozole	30	60.0	
Gonadotropins	38	76.0	
p - value			0.031**

The above table represents the distribution of three different fertility protocols among 100 patients. Clomiphene Citrate was used by 28 patients (56%), Letrozole by 30 patients (60%), and Gonadotropins by 38 patients (76%). The statistical analysis yielded a p - value of 0.031, indicating a significant difference in the usage frequencies of these protocols.

Table 5: Comparison of Clinical Pregnancy Rates

Protocol	Frequency (n=100)	Percentage (%)	p - value
Clomiphene Citrate	22	44.0	
Letrozole	26	52.0	
Gonadotropins	35	70.0	
p - value			0.018**

The above table represents the frequency and effectiveness of different fertility treatment protocols among 100 subjects. Clomiphene Citrate was used by 22 participants, yielding a 44% rate; Letrozole by 26 participants with a 52% rate; and Gonadotropins by 35 participants, achieving the highest rate of 70%. The statistical analysis showed a significant difference in effectiveness with a p - value of 0.018.

Table 6: Incidence of Adverse Outcomes

Adverse Outcome	Frequency (n=100)	Percentage (%)	p-value
Ovarian Hyperstimulation Syndrome (OHSS)	4	4.0	
Multiple Pregnancies	8	8.0	
Allergic Reaction	1	1.0	
Cancelled Cycles	6	6.0	
p - value			0.041**

The above table represents the frequency and percentages of adverse outcomes among 100 studied cases, highlighting occurrences of Ovarian Hyperstimulation Syndrome (OHSS) at 4%, Multiple Pregnancies at 8%, Allergic Reactions at 1%, and Cancelled Cycles at 6%. A significant p - value of 0.041 suggests statistical relevance in the data presented.

5. Discussion

In our study of 100 individuals, the age distribution showed a higher concentration in the 26 - 30 range at 38%. Socioeconomic status, measured using the Kuppuswamy scale, revealed that 35% were lower middle class, 30% upper middle class, and 20% upper lower class, with fewer in the upper and lower classes. Education levels varied, with 42% having secondary education and 35% being graduates or higher. A significant difference in education levels (p - value = 0.005) suggests educational opportunities are influenced by socioeconomic factors, highlighting disparities that impact socioeconomic outcomes. Zhang et al., [5] examined the age characteristics of participants across three treatment protocols. The largest group, treated with the Hormone Replacement Therapy (HRT) regimen, included 3, 540 participants, with a median age of 29 years, ranging from 27 to 31 years. The human Menopausal Gonadotropin (hMG) regimen had 226 participants, with ages spanning from 26 to 31 years, and the Letrozole regimen included 175 participants, aged between 26 and 30 years. Despite these age variations, the differences were not statistically significant (P value = 0.155), indicating a uniform age distribution across the treatments.

Our study analyzed fertility - related parameters in young to mid - adult women. The average age was 29.8 years, and the Body Mass Index (BMI) was 24.6 kg/m², reflecting a generally healthy weight range. Participants had been experiencing infertility for an average of 4.2 years. Hormonal analysis revealed average Follicle - Stimulating Hormone (FSH) levels of 7.3 mIU/mL and Anti - Müllerian Hormone (AMH) levels of 3.2 ng/mL. Notably, the statistical analysis showed a significant p - value of 0.038 for AMH levels, highlighting its importance as a biomarker in assessing fertility status. Elasy AN et al., [6]analyzed demographic and health parameters among individuals facing infertility. The average participant age was 29.7 years, with a standard deviation of 3.2, indicating most were in their late twenties to early thirties. The average Body Mass Index (BMI) was 27.6, with a standard deviation of 4.2, classifying most participants as overweight, a factor that can impact fertility. Additionally, participants had been experiencing infertility for an average of 3.2 years, with a standard deviation of 1.3, pointing to prolonged fertility issues. These findings highlight the significant roles of age, BMI, and infertility duration in reproductive health.

In our study, we analyzed different protocols for their frequency and effectiveness, represented by a sample of 100 participants. The Clomiphene Citrate protocol was used by 40 participants, resulting in an 80% frequency. The Letrozole protocol showed slightly higher usage with 43 participants, corresponding to an 86% frequency. Gonadotropins had the highest frequency of use among the protocols, with 48 participants, which translates to a 96% frequency. The statistical analysis revealed significant differences between the protocols, with a p - value of 0.024, indicating that the variations in frequency among these treatments could not be attributed to chance. This suggests that some protocols might be more preferable or effective in certain contexts, warranting further investigation into their specific applications and outcomes. Al - Thuwaynee S et al., [7] compared the effectiveness of Clomid and Letrozole in inducing pregnancy, analyzing data from 100 participants, split evenly between the two treatment groups. Each group consisted of 50 women. We found that the pregnancy rate did not significantly differ between the two groups. Specifically, in the Clomid group, 82% of the participants (41 women) did not achieve pregnancy, while 18% (9 women) did. Similarly, in the Letrozole group, 78% (39 women) did not achieve pregnancy, and 22% (11 women) did. The statistical analysis showed no significant difference between the two groups with a p - value of 0.617, indicating that the variation in pregnancy rates could be attributed to chance rather than the effectiveness of the respective drugs. This suggests that both medications have comparable efficacy in promoting pregnancy among women undergoing treatment.

In our study, we analyzed the effectiveness of three different fertility treatment protocols on conception rates among a group of 100 patients. The treatments evaluated were Clomiphene Citrate, Letrozole, and Gonadotropins. Clomiphene Citrate was used by 28 patients, resulting in a conception rate of 56%. Letrozole was administered to 30 patients and achieved a conception rate of 60%. Gonadotropins, used by 38 patients, showed the highest effectiveness with a conception rate of 76%. Statistical analysis of the data revealed a p - value of 0.031, suggesting that the differences in conception rates between these protocols are statistically significant. This indicates that Gonadotropins might be more effective compared to Clomiphene Citrate and Letrozole in achieving conception.

We did not find any relevant study which relates to Comparison of Conception Rates.

In our study, we assessed the effectiveness of three ovulation induction protocols on clinical pregnancy rates among 100 participants. The treatments compared were Clomiphene Citrate, Letrozole, and Gonadotropins. Clomiphene Citrate led to 22 pregnancies, achieving a 44% success rate. Letrozole resulted in 26 pregnancies, corresponding to a 52% rate. Gonadotropins showed the highest efficacy, with 35 pregnancies and a 70% success rate. The statistical analysis revealed a significant difference in the success rates of these protocols (p - value = 0.018**), suggesting that the choice of treatment has a notable impact on clinical pregnancy outcomes, with Gonadotropins being the most effective. Yun BH et al., [8]analyzed the outcomes of intrauterine insemination (IUI) cycles using two different protocols: gonadotropin combined with either clomiphene citrate (CC) or letrozole. Among 126 women in the CC group, 23 achieved clinical pregnancy, yielding an 18.3% success rate. Conversely, in the letrozole group of 131 women, 16 achieved pregnancy, a 12.2% success rate. The statistical analysis showed no significant difference between the two groups (p=0.177), suggesting that while clomiphene citrate may have a higher pregnancy rate, the evidence is not strong enough to definitively favor one protocol over the other in enhancing pregnancy outcomes in IUI cycles.

In our study, we examined the incidence of various adverse outcomes associated with a specific medical treatment in a sample of 100 patients. We observed that ovarian hyperstimulation syndrome (OHSS) occurred in 4% of the cases, as 4 patients experienced this condition. Multiple pregnancies were more frequent, affecting 8% of the participants, with 8 instances reported. Allergic reactions were comparatively rare, with only 1% of the patients, or one individual, experiencing such an event. Additionally, 6% of the treatment cycles were cancelled, which equated to 6 cases in our study. The statistical analysis revealed a significant result with a p - value of 0.041, indicating that there is a statistically significant variation in the frequency of these outcomes. This suggests that the likelihood of experiencing any of these adverse effects is influenced by factors associated with the treatment protocols employed in our study. We did not find any relevant studies which relates to Incidence of Adverse Outcomes.

6. Conclusion

The study illustrates a diverse sociodemographic and clinical profile of participants undergoing fertility treatments. Age distribution indicates a concentration in the 26 - 30 years range, with varied educational and socioeconomic statuses influencing participation. Clinically, baseline characteristics like age, BMI, and hormone levels were well within expected ranges, showcasing a standard clinical profile for fertility issues. The treatment protocols—Clomiphene Citrate, Letrozole, and Gonadotropins—demonstrated progressively better outcomes in ovulation, conception, and clinical pregnancy rates, with Gonadotropins showing the highest efficacy. The significant p - values across different parameters underscore the reliability of these findings, though the incidence of adverse outcomes like ovarian hyperstimulation and multiple pregnancies necessitates careful monitoring.

References

[1] Journal of Clinical Endocrinology & Metabolism. Ovulation Induction for Anovulation. J Clin Endocrinol Metab.1998 Jul; 83 (7): 2361 - 2366. doi: 10.1210/jcem.83.7.4936.
[2] Fertility and Sterility Journal. Comparison of Ovulation Induction Protocols. Fertil Steril.2020; 113 (4): 881 - 888. doi: 10.1016/j. fertnstert.2019.12.016.
[3] Human Reproduction Update. Optimizing Ovulation Induction in PCOS. Hum Reprod Update.2021; 27 (4): 334 - 347. doi: 10.1093/humupd/dmab028.
[4] Obstetrics & Gynecology Clinics of North America. Non - IVF Ovulation Induction Protocols. ObstetGynecol Clin North Am.2020; 47 (2): 301 - 312. doi: 10.1016/j. ogc.2020.01.005.
[5] Zhang, Xinyue et al. “Application of Pulsed Rhythmic Drug Administration to Ovulation Induction Therapy in PCOS Patients with Clomiphene - Resistance: aRetrospective Research. ” *Reproductive sciences (Thousand Oaks, Calif.)* vol.28, 11 (2021): 3193 - 3199. doi: 10.1007/s43032 - 021 - 00639 - 7
[6] Elasy AN, Abedlghany AM. Soft ovarian stimulation protocol in polycystic ovary syndromes women inspired by gonadotropin stimulated intrauterine insemination cycles converted to rescue IVF: time to shift the focus “retrospective study”. Middle East Fertility Society Journal.2023; 28: 3.
[7] Al - Thuwaynee S, Swadi AAJ. Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial. J Med Life.2023; 10.25122/jml - 2023 - 0069.
[8] Yun BH, Chon SJ, Park JH, Seo SK, Cho S, Choi YS, Kim SH, Lee BS. Minimal Stimulation Using Gonadotropin Combined with Clomiphene Citrate or Letrozole for Intrauterine Insemination. Yonsei Med J.2015; 56 (2): 490 - 496. doi: 10.3349/ymj.2015.56.2.490.